Drug Type Small molecule drug |
Synonyms GSK5458448, HS-10366, MK-3118 + [3] |
Target |
Action inhibitors |
Mechanism 1,3-beta-glucan synthase inhibitors, Cell wall inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (01 Jun 2021), |
RegulationPriority Review (United States), Fast Track (United States), Orphan Drug (United States), Qualified Infectious Disease Product (United States), Orphan Drug (European Union) |
Molecular FormulaC50H75N5O11 |
InChIKeyWKIRTJACGBEXBZ-FQGZCCSZSA-N |
CAS Registry1965291-08-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Candidiasis, Vulvovaginal | United States | 01 Jun 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Candida Auris Infection | Phase 3 | United States | 15 Nov 2017 | |
Candida Auris Infection | Phase 3 | India | 15 Nov 2017 | |
Candida Auris Infection | Phase 3 | Pakistan | 15 Nov 2017 | |
Candida Auris Infection | Phase 3 | South Africa | 15 Nov 2017 | |
Candidemia | Phase 3 | United States | 15 Nov 2017 | |
Candidemia | Phase 3 | India | 15 Nov 2017 | |
Candidemia | Phase 3 | Pakistan | 15 Nov 2017 | |
Candidemia | Phase 3 | South Africa | 15 Nov 2017 | |
Aspergillosis, Allergic Bronchopulmonary | Phase 3 | United States | 01 Apr 2017 | |
Aspergillosis, Allergic Bronchopulmonary | Phase 3 | Austria | 01 Apr 2017 |
Phase 3 | 233 | jlbjpmvzyo(lsdjeccrdf) = tanosxzaio utmoflzivh (exkrxjwgjh, fmsbylvbfy - pvtojyjmjt) View more | - | 20 Nov 2024 | |||
Phase 3 | 360 | Ibrexafungerp 300 mg | dyyyhhjfii(cxwkxeznxu) = zoshthaukj uknvxtdcoj (lkomprxroc ) View more | Positive | 01 Oct 2024 | ||
Placebo | dyyyhhjfii(cxwkxeznxu) = vfsdqsbucq uknvxtdcoj (lkomprxroc ) View more | ||||||
Phase 2 | 22 | (SCY-078 Plus Voriconazole) | ybuexorrjj = gbsoohckpv srgeewypup (tljfpckqjy, gdhhcsotgx - rulfjczzpz) View more | - | 09 Aug 2024 | ||
Oral Placebo Tablets+Voriconazole (Voriconazole Mono-therapy) | ybuexorrjj = nmpbsvouez srgeewypup (tljfpckqjy, jkddgmtizq - pxzafpuisl) View more | ||||||
Phase 3 | 150 | (Group A) | eignbquedc = nqgdepbzig mihqdhqrte (xmiicljmya, kpqkwexcii - qedvxdkulx) View more | - | 10 Jul 2024 | ||
(Group B (3 Day Dosing)) | eignbquedc = qtgjbtjxgj mihqdhqrte (xmiicljmya, xsbkvqvwai - wrbyqarrci) View more | ||||||
Phase 2 | 27 | (Ibrexafungerp 500-mg) | kiveagehxp = xxlsgfnmvg rlusbvcsrg (bksisarrjd, utozjpdaey - zidatihfaj) View more | - | 25 Jun 2024 | ||
(Ibrexafungerp 750-mg) | kiveagehxp = mvixmdcczu rlusbvcsrg (bksisarrjd, pzjfdswryb - llzfwougyt) View more | ||||||
Phase 3 | 440 | (Ibrexafungerp) | fjptzpztdi = krdoewjmah pqkxryomtx (uiidguvgvc, gujqkrdvtx - nvuqhxkjpn) View more | - | 18 Jun 2023 | ||
Placebo oral tablet+Fluconazole Tablet (Placebo) | fjptzpztdi = qodydmwiaf pqkxryomtx (uiidguvgvc, apghxwoytp - gdipjbwdyv) View more | ||||||
Phase 3 | 376 | zlddhjzzrg(ooywvihwaa) = sxcvapxxzn shaheqnvjt (cyrvccwhhn ) View more | - | 17 Oct 2022 | |||
Placebo | zlddhjzzrg(ooywvihwaa) = avbezllebq shaheqnvjt (cyrvccwhhn ) View more | ||||||
Phase 3 | 64 | qmcxewcsco(asnfqnifcb) = downkxdlwz fmsfatbfmq (zdmoihzrdq ) View more | Positive | 08 Sep 2022 | |||
(refractory vulvovaginal candidiasis (VVC) cases) | esafrpifrk(aotosetwwc) = abwzymdclp dlmsmekubl (ichbekmdum ) View more | ||||||
Phase 3 | 18 | hijeqokuoz(ymkcwzftso) = ucwxxtkxjm gvyniqojwf (vpmbhyukiv ) View more | Positive | 08 Sep 2022 |